Pulmovant
The Associate Director, Drug Product serves as a technical leader for Pulmovant's inhaled dry powder product portfolio, overseeing product performance, manufacturability, and the transition to registration and commercial manufacturing. This role involves partnering with internal teams and external CDMOs to resolve technical risks and ensure the successful development of drug products. The position requires providing scientific oversight and leading contributions to CMC submissions for clinical and commercial stages.
Pulmovant is a clinical-stage biopharmaceutical company singularly focused on developing innovative inhaled therapies for pulmonary diseases, including pulmonary hypertension. The company's lead candidate, mosliciguat, is a potentially first-in-class once-daily inhaled treatment with a differentiated soluble guanylate cyclase (sGC) activation mechanism. Pulmovant is advancing mosliciguat through clinical trials with the goal of transforming the treatment paradigm for patients with pulmonary diseases.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Pulmovant.
Pulmovant completes enrollment for PH-ILD treatment trial
1 month ago